YGEN Stock Overview
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally.
Yourgene Health Plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.047|
|52 Week High||UK£0.16|
|52 Week Low||UK£0.045|
|1 Month Change||-24.80%|
|3 Month Change||-24.80%|
|1 Year Change||-67.02%|
|3 Year Change||-60.00%|
|5 Year Change||-37.33%|
|Change since IPO||-70.63%|
Recent News & Updates
Yourgene Health Plc (LON:YGEN) Shares Could Be 34% Above Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Yourgene Health Plc...
|YGEN||GB Medical Equipment||GB Market|
Return vs Industry: YGEN underperformed the UK Medical Equipment industry which returned -19.9% over the past year.
Return vs Market: YGEN underperformed the UK Market which returned -14.4% over the past year.
|YGEN Average Weekly Movement||6.2%|
|Medical Equipment Industry Average Movement||6.0%|
|Market Average Movement||5.5%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.9%|
Stable Share Price: YGEN is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: YGEN's weekly volatility (6%) has been stable over the past year.
About the Company
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down’s syndrome, Edwards' syndrome, and Patau’s Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient’s response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing.
Yourgene Health Plc Fundamentals Summary
|YGEN fundamental statistics|
Is YGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|YGEN income statement (TTM)|
|Cost of Revenue||UK£16.20m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0026|
|Net Profit Margin||-5.10%|
How did YGEN perform over the long term?See historical performance and comparison